Business
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen
LONDON, February 25, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study.1 In adults living with HIV on stable therapy, a regimen of lotivibart (N6LS), a broadly neutralising antibody, administered every four months combined with monthly intramuscular (IM) long-acting cabotegravir (CAB LA), maintained viral suppression in
About this update from Shionogi & Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":320,"height":296,"url":"https://media.zenfs.com/en/business-wire.com/c6d333977aac6304081296403ec5f81e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PnPi8.1ml4lJ_B880XtBqQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTU5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c6d333977aac6304081296403ec5f81e","width":320,"height":296}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"94% of adults on stable therapy maintained viral suppression with intravenous lotivibart dosed every four months in combination with long-acting cabotegravir","length":157,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"These phase IIb results reinforce lotivibart’s ultra long-acting potential, with the trial progressing to evaluate a twice-yearly intravenous dosing interval","length":157,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":314,"olType":false},{"type":"text","content":"LONDON, February 25, 2026--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study.1 In adults living with HIV on stable therapy, a regimen of lotivibart (N6LS), a broadly neutralising antibody, administered every four months combined with monthly intramuscular (IM) long-acting cabotegravir (CAB LA), maintained viral suppression in 94% of participants receiving lotivibart intravenously (IV) and 82% subcutaneously (SC), compared with 88% in the standard of care group.","length":655,"tagName":"p"},{"type":"text","content":"These favourable data reinforce lotivibart’s ultra long-acting potential (dosing every four months or longer) and support the progression of the study, which will evaluate a twice-yearly IV dosing interval for lotivibart.","length":221,"tagName":"p"},{"type":"text","content":"Results were presented today at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, Colorado.","length":129,"tagName":"p"},{"type":"text","content":"Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: "These positive 12-month data from EM...